Rocío-V. Gamboa-Cárdenas

Rocío-V. Gamboa-Cárdenas

Auto-generated profile, based on publicly available information

Rocío-V. Gamboa-Cárdenas

Servicio de Reumatología, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Av. Miguel Grau 800, La Victoria, 15033, Lima, Peru.

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2017 in Lupus
Verified
Journal Article
Closed access
MUM F Ugarte-Gil
M F Ugarte-Gil
DWD Wojdyla
D Wojdyla
CPC A Pastor-Asurza
C A Pastor-Asurza
RGR V Gamboa-Cárdenas
R V Gamboa-Cárdenas
EAE M Acevedo-Vásquez
E M Acevedo-Vásquez
BPB A Pons-Estel
B A Pons-Estel
The purpose of this paper is to determine the factors predictive of flares in systemic lupus erythematosus (SLE) patients. A case-control study nested within the Grupo Latino Americano De Estudio de Lupus (GLADEL) cohort was conducted. Flare was defined as an increase ≥4 points in the SLEDAI. Cases were defined as patients with at least one flare. Controls were selected by matching cases by length of follow-up. Demographic and clinical manifestations were systematically recorded by a common protocol. Glucocorticoid use was recorded as average daily dose of prednisone and antimalarial use as percentage of time on antimalarial and categorized as never (0%), rarely (>0–25%), occasionally (>25%–50%), commonly (˃50%–75%) and frequently (˃75%). Immunosuppressive drugs were recorded as used or not used. The association between demographic, clinical manifestations, therapy and flares was examined using univariable and multivariable conditional logistic regression models. A total of 465 cases and controls were included. Mean age at diagnosis among cases and controls was 27.5 vs 29.9 years, p = 0.003; gender and ethnic distributions were comparable among both groups and so was the baseline SLEDAI. Independent factors protective of flares identified by multivariable analysis were older age at diagnosis (OR = 0.929 per every five years, 95% CI 0.869–0.975; p = 0.004) and antimalarial use (frequently vs never, OR = 0.722, 95% CI 0.522–0.998; p = 0.049) whereas azathioprine use (OR = 1.820, 95% CI 1.309–2.531; p < 0.001) and SLEDAI post-baseline were predictive of them (OR = 1.034, 95% CI 1.005–1.064; p = 0.022). In this large, longitudinal Latin American cohort, older age at diagnosis and more frequent antimalarial use were protective whereas azathioprine use and higher disease activity were predictive of flares.

3 June 2019 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
RGRocio V Gamboa-Cárdenas
Rocio V Gamboa-Cárdenas
MUManuel F. Ugarte-Gil
Manuel F. Ugarte-Gil
MLMassardo Loreto
Massardo Loreto
MSMónica P. Sacnun
Mónica P. Sacnun
VSVerónica Saurit
Verónica Saurit
BPBernardo A. Pons-Estel
Bernardo A. Pons-Estel

30 June 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
RGRocío-V. Gamboa-Cárdenas
Rocío-V. Gamboa-Cárdenas
SBSilvia Barzola-Cerrón
Silvia Barzola-Cerrón
DTDenisse Toledo-Neira
Denisse Toledo-Neira
CRCristina Reátegui-Sokolova
Cristina Reátegui-Sokolova
VPVíctor Pimentel-Quiroz
Víctor Pimentel-Quiroz
MUManuel Ugarte-Gil
Manuel Ugarte-Gil

24 September 2019 in Lupus
Verified
Journal Article
Closed access
PDF file
CRC Reátegui-Sokolova
C Reátegui-Sokolova
ZRZ Rodríguez-Bellido
Z Rodríguez-Bellido
RGR V Gamboa-Cárdenas
R V Gamboa-Cárdenas
MMM Medina
M Medina
FZF Zevallos
F Zevallos
MUM F Ugarte-Gil
M F Ugarte-Gil
The aim of this study was to determine whether remission and low disease activity state protect systemic lupus erythematosus patients from being hospitalized. Patients from the Almenara Lupus Cohort were included. Visits were performed every 6 months. Variables were measured at each visit. Hospitalizations were evaluated in the interval between two visits. Remission was defined as: a SLEDAI-2 K of 0, prednisone ≤5 mg/day and immunosuppressants on maintenance dose; low disease activity state as: a SLEDAI-2 K of ≤4, prednisone ≤7.5 mg/day and immunosuppressants on maintenance dose. Univariable and multivariable interval-censored survival regression models were used. In multivariable analysis, possible confounders were gender, age at diagnosis, socioeconomic status, educational level, disease duration, antimalarial use, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI) and Charlson comorbidity index. Confounders were determined in the same visit as disease activity state. Of the 308 patients, 92.5% of them (n = 285) were women, had a mean age at diagnosis of 34.8 (13.4) years and a disease duration of 7.7 (6.5) years. At baseline the mean SDI was 1.13 (1.34). A total of 163 of the patients were hospitalized. In the multivariable analysis remission (hazard ratio 0.445 (0.274–0.725), P = 0.001) and low disease activity state (relative risk 0.504 (0.336–0.757), P = 0.001) at baseline were found to decrease the risk of hospitalization in systemic lupus erythematosus patients. A total of 158 hospitalizations presented a discernible cause. Disease activity was the most common cause of hospitalization, with 84 admissions (53.16%), the majority, 38, was due to active kidney disease (45.23%). Remission and low disease activity state decreased the risk of hospitalizations in these systemic lupus erythematosus patients. Disease activity, particularly renal, was the most frequent cause of hospitalization.

15 September 2020 in Global Rheumatology
Verified
Journal Article
Open access
MUManuel F. Ugarte-Gil
Manuel F. Ugarte-Gil
CMClaudia D. L. Marques
Claudia D. L. Marques
DADeshire Alpizar-Rodriguez
Deshire Alpizar-Rodriguez
GPGuillermo J. Pons-Estel
Guillermo J. Pons-Estel
DXDaniel Xibille-Friedmann
Daniel Xibille-Friedmann
JYJinoos Yazdany
Jinoos Yazdany
Objective: To compare the characteristics of patients with rheumatic diseases and COVID-19 reported from Latin American countries with those from the rest of the world. Methods: Patients from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry were included. Details regarding demographics, rheumatic disease features, comorbidities, COVID-19 diagnosis and treatment, and outcomes were examined. Chi-squared and t-tests were used to compare associations between groups (Latin America vs. rest of the world). Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of hospitalization (yes/no) and ventilatory support (not hospitalized or supplementary oxygen only vs. non-invasive, invasive ventilation, or ECMO); Poisson models were used to estimate ORs and 95% CIs of mortality. Results: Seventy-four patients from Latin America and 583 patients from the rest of the world were included. The most frequent rheumatic diseases in both groups were rheumatoid arthritis (35% and 39%, respectively) and systemic lupus erythematosus (22% and 14% respectively). Mortality was similar between groups (12% Latin America vs 11% rest of the world, p=0.88. However, Latin American patients in the registry had a higher odds of requiring non-invasive or invasive ventilation, after adjustment [OR= 2.29, 95%CI (1.29, 4.07), p less than 0.01].. Conclusion: Latin American patients with rheumatic disease and COVID-19 reported to this global registry presented a higher need for ventilatory support, however experienced a similar mortality than patients from the rest of the world.

13 November 2025 in The Lancet Rheumatology
Verified
Journal Article
Closed access
PSPedro Santos-Moreno
Pedro Santos-Moreno
RSRodrigo García Salinas
Rodrigo García Salinas
CUCarlo Vinicio Caballero Uribe
Carlo Vinicio Caballero Uribe
MBMaría Lorena Brance
María Lorena Brance
NZNicolas M Marín Zúcaro
Nicolas M Marín Zúcaro
ESEnrique R. R. Soriano
Enrique R. R. Soriano